Review article: The effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 12, 2011, Pages 1261-1272

  Veerappan, S G ^a,b   O'Morain, C A ^a   Daly, J S ^b   Ryan, B M ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID; GLUCOCORTICOID; INFLIXIMAB; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE STRUCTURE; BONE TURNOVER; CROHN DISEASE; ENTERITIS; FRACTURE; HUMAN; MAINTENANCE THERAPY; OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; OSTEOPOROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956133759     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04667.x     Document Type: Article

References (71)

1. Genant HK, Mall JC, Wagonfeld JB, et al. Skeletal demineralization and growth retardation in inflammatory bowel disease. Invest Radiol 1976; 11: 541-9. (Pubitemid 8021239)
2. Vestergaard P, Mosekilde F,. Fracture risk in patients with coeliac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16416 patients in Denmark. Am J Epidemiol 2002; 156: 1-10. (Pubitemid 34680618)
3. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004; 53: 251-5. (Pubitemid 38125514)
4. Silvennoinen JA,. Relationship between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Int Med 1996; 239: 131-7.
5. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157-63. (Pubitemid 27304813)
6. Silvennoinen JA, Karttunen TJ, Niemelia SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
7. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone mineral density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.
8. Adinoff AD, Hollister JR,. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-8. (Pubitemid 13074917)
9. Compston JE,. Detection of osteoporosis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 931-3. (Pubitemid 27448059)
10. Robinson RJ, Iqbal SJ, Al-Azzani F, et al. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 21-5. (Pubitemid 28057400)
11. Szulc P, Meunier PJ,. Is vitamin-K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001; 357: 1995-6. (Pubitemid 32592384)
12. Hyams JS, Wyzga N, Kreutzer DL, et al. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997; 24: 289-95. (Pubitemid 27199618)
13. Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-22.
14. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis. Gut 1997; 40: 313-9. (Pubitemid 27145642)
15. Robinson RJ, Krzywicky T, Almond L, et al. Effect of low-impact exercise program on bone mineral density in Crohn's disease. A randomized controlled study. Gastroenterology 1998; 115: 36-41. (Pubitemid 28307285)
16. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1895-902. (Pubitemid 35253005)
17. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of glucocorticoid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60. (Pubitemid 32729372)
18. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
19. Gregorio LH, Lacativa PG, Melazzi AC, et al. Glucocorticoid induced osteoporosis. Arq Bras Endocrinol Metab 2006; 50: 793-801.
20. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997; 99: 1699-703. (Pubitemid 27163821)
21. Bickel M, Axtelius B, Solioz C, et al. Cytokine gene expression in chronic periodontitis. J Clin Periodontol 2001; 28: 840-7. (Pubitemid 33755445)
22. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002; 4: 281-9. (Pubitemid 34947141)
23. Origuchi T, Migita K, Nakashima T, et al. IL-1-mediated expression of membrane type matrix-metalloproteinase in rheumatoid osteoblasts. Clin Exp Rheumatol 2000; 18: 333-9. (Pubitemid 30409102)
24. Oelzner P, Franke S, Muller A, et al. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 841-7. (Pubitemid 29507366)
25. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002; 41: 329-37. (Pubitemid 34537871)
26. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
27. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297-301. (Pubitemid 32579119)
28. Lanfranchi GA, Tragnone A,. Serum and faecal tumour necrosis factor-alpha as marker of intestinal inflammation. Lancet 1992; 339: 1053.
29. Lin CL, Moniz C, Chambers TJ, et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 1263.
30. Kumar S, Votta BJ, Rieman DJ, et al. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 2001; 187: 294-303. (Pubitemid 32378354)
31. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17: 695-702. (Pubitemid 34246645)
32. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276: 563-8. (Pubitemid 32050352)
33. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-8. (Pubitemid 32038586)
34. Zou W, Hakim I, Tschoep K, et al. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001; 83: 70-83.
35. Fuller K, Murphy C, Kirstein B, et al. TNF alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108-18. (Pubitemid 34164059)
36. Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001; 276: 49343-9.
37. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956-64.
38. Taichman RS, Hauschka PV,. Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation 1992; 16: 587-601.
39. Pfeilschifter J, Chenu C, Bird A, et al. Interleukin 1 and tumour necrosis factor stimulate the formation of human osteoclast like cells in vitro. J Bone Miner Res 1989; 4: 113-8. (Pubitemid 19079131)
40. Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin 1 beta and tumour necrosis factor α, but not interleukin 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25: 255-9. (Pubitemid 29406050)
41. Hofbauer LC, Dunstan CR, Spelsberg TC, et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-81. (Pubitemid 28484803)
42. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 684-9. (Pubitemid 26426469)
43. Lichtenstein GR,. Evaluation of bone mineral density in IBD: current safety focus. Am J Gastroenterol 2003; 98 (Suppl. 12): S24-30. (Pubitemid 38044604)
44. Nanes MS,. TNF-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003; 321: 1-15. (Pubitemid 37421390)
45. Aubin JE, Bonnelye E,. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 11: 905-13. (Pubitemid 32044070)
46. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
47. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-84.
48. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57. (Pubitemid 33022095)
49. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-11. (Pubitemid 34087933)
50. Van den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85. (Pubitemid 36666774)
51. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
52. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
53. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
54. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
55. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
56. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
57. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004; 20: 607-14. (Pubitemid 39279048)
58. Ryan BM, Russel MGVM, Schurgers L, et al. Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004; 20: 851-7. (Pubitemid 39424892)
59. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40: 55-63. (Pubitemid 44378078)
60. Miheller P, Muzes G, Zagoni T, et al. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis 2006; 2: 201-6.
61. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 2006; 1068: 543-56. (Pubitemid 43832924)
62. Mauro M, Radovic V, Armstrong D,. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 2007; 21: 637-42. (Pubitemid 350200498)
63. Bernstein M, Irwin S, Greenberg GR,. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100: 2031-5.
64. Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 2007; 13: 1379-84. (Pubitemid 350206849)
65. Plosker GL, Lyseng-Williamson KA,. Adalimumab in Crohn's disease. Biodrugs 2007; 21: 125-32.
66. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
67. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
68. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimuma induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
69. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
70. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss? Ann Rheum Dis 2009; 68: 373-6.
71. Abu-Amer Y, Erdmann J, Alexopoulou L, et al. Tumour necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275: 27307-10.